Asset Details
Do you wish to reserve the book?
Comparative efficacy and safety of topical caspofungin 0.5% and voriconazole 1% for fungal keratitis: a pilot clinical trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparative efficacy and safety of topical caspofungin 0.5% and voriconazole 1% for fungal keratitis: a pilot clinical trial
Do you wish to request the book?
Comparative efficacy and safety of topical caspofungin 0.5% and voriconazole 1% for fungal keratitis: a pilot clinical trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparative efficacy and safety of topical caspofungin 0.5% and voriconazole 1% for fungal keratitis: a pilot clinical trial
2025
Overview
To compare the efficacy of topical caspofungin 0.5% with topical voriconazole 1% in patients with fungal keratitis. In this pilot clinical trial, thirty-four eyes from 34 patients diagnosed with fungal keratitis, confirmed by positive smear or culture results or in vivo confocal microscopy (IVCM), were included in the study. Patients were randomized to receive either topical caspofungin 0.5% or voriconazole 1%. The primary outcome measure was best spectacle-corrected visual acuity (BSCVA) at 3 months of follow-up. Secondary outcomes were the percentage of healed ulcers, time to healing, and scar size. After 3 months of treatment, the mean BSCVA was1.17 ± 0.85 logarithm of minimum angle of resolution (LogMAR) units in the caspofungin group and 0.49 ± 0.56 LogMAR units in the voriconazole group and the difference between two groups was 0.18 LogMAR (95% CI, -0.14 to 0.51 P = 0.276). The final mean scar size was similar between the caspofungin group (2.47 ± 2.1) and the voriconazole group (3.09 ± 1.11) (P = 0.254, 95% CI, -1.88 to 0.50 mm). The percentage of cases healed was 70.6% (12/17) in the caspofungin group and 100% (17/17) in the voriconazole group (P = 0.060, Hazard ratio ,2.06 95% CI,0.97 to 4.37). Fusarium species were the most common species (9/34; 26.5% cases). Complete stromal healing occurred in all 5 patients infected with Fusarium species who were treated with voriconazole 1%. one out of 4 patients in the caspofungin group showed complete healing (P = 0.048). The patients in caspofungin group had large mean infiltration size 4.81± 1.60 mm, (P = 0.255) than 2.90± 1.60 mm in voriconazole group and deeper infiltration depth 25 ±13% than 15± 9%voriconazole group (P = 0.120). This study indicates that topical caspofungin 0.5% may be effective as topical voriconazole 1%, making caspofungin 0.5% a viable primary treatment option for patients with fungal keratitis.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 631/326
/ 692/699
/ Acuity
/ Adult
/ Aged
/ Antifungal Agents - administration & dosage
/ Antifungal Agents - adverse effects
/ Antifungal Agents - therapeutic use
/ Caspofungin - administration & dosage
/ Caspofungin - adverse effects
/ Caspofungin - therapeutic use
/ Cornea
/ Diabetes
/ Eye Infections, Fungal - drug therapy
/ Eye Infections, Fungal - microbiology
/ Female
/ Fusarium
/ Humanities and Social Sciences
/ Humans
/ Male
/ Patients
/ Science
/ Steroids
/ Topical
/ Ulcers
/ Visual Acuity - drug effects
/ Voriconazole - administration & dosage
